Back to search

Article

Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform

2025-11-09

Abstract excerpt

<h4>STRUCTURED ABSTRACT</h4> <h4>INTRODUCTION</h4> The NULISASeq™ CNS Disease Panel has high potential for AD diagnosis, but the comparability of serum vs. plasma remains unclear. <h4>METHODS</h4> We compared its performance on 43 matched serum-plasma pairs from a memory clinic cohort. <h4>RESULTS</h4> The panel reproducibly quantified 124 targets (mean CV=4.9%) with high detectability (mean=95.7%). Serum-plas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
561e2327-d84e-5aa1-b91c-672964102988
DOI
10.1101/2025.11.08.25339626
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformDOI 10.1101/2025.11.08.25339626
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer's disease phenotypes in a large mixed-dementia cohort.Semantic proximity
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s diseaseSemantic proximity
Deep Plasma Proteomics Reveals Shared and Disease-Specific Molecular Signatures in Alzheimer’s Disease and Frontotemporal DementiaSemantic proximity
Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity
Plasma and CSF proteomic signatures related to Alzheimer’s, α-synuclein, or vascular pathologies and clinical declineSemantic proximity
A genetic and proteomic comparison of key AD biomarkers across tissuesSemantic proximity
Multiplex plasma profiling of synaptic biomarkers in Alzheimer’s disease using NULISA: early alterations, APOE genotype effects, and pTau217 associationsSemantic proximity
Dementia etiology classification using NULISA plasma biomarkers and machine learningSemantic proximity
Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer’s diseaseSemantic proximity
Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental ValidationSemantic proximity
Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and PrognosticsSemantic proximity
Select a neighboring publication to make it the new centre.